| Basics |
MEI Pharma, Inc.
MEI Pharma Inc is an oncology company focused on the clinical development of novel therapeutics for cancer. The Company's portfolio of drug candidates includes Pracinostat, an oral histone deacetylase inhibitor.
|
| IPO Date: |
January 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$100.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.10 | 3.12%
|
| Avg Daily Range (30 D): |
$0.18 | 6.02%
|
| Avg Daily Range (90 D): |
$0.22 | 4.76%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.56M |
| Avg Daily Volume (30 D): |
.29M |
| Avg Daily Volume (90 D): |
.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
285 |
| Avg Trade Size (Sh.) (30 D): |
212 |
| Avg Trade Size (Sh.) (90 D): |
118 |
| Institutional Trades |
| Total Inst.Trades: |
133 |
| Avg Inst. Trade: |
$1.54M |
| Avg Inst. Trade (30 D): |
$.76M |
| Avg Inst. Trade (90 D): |
$.81M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.3M |
| Avg Closing Trade (30 D): |
$.56M |
| Avg Closing Trade (90 D): |
$.56M |
| Avg Closing Volume: |
50.8K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-2.39
|
$-.4
|
$-2.39
|
|
Diluted EPS
|
$-2.39
|
$-.4
|
$-2.39
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -15.95M
|
$ -2.69M
|
$ -15.95M
|
|
Operating Income / Loss
|
$ -17.46M
|
$ -2.88M
|
$ -17.46M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Apr 17, 2023:
1:20
|
|
Dec 19, 2012:
1:6
|
|
Mar 31, 2010:
1:10
|
|
|
|
